Plate Nº 45 · recorded October 10, 2026
Neuroscience & MindReported finding
Protein p11 Amplifies Signals Across 24 Drug-Targeted Receptors, Study Finds
Karolinska researchers screened 211 human cell receptors and found that protein p11 interacts with about 24 previously unknown drug targets, suggesting new paths for treating pain, inflammation, and depression.
By James Calloway3 min read547 words
In brief
- Researchers screened all 211 human GPCRs and identified about two dozen previously unknown p11 interactors
- Roughly one-third of approved medicines act through GPCRs
- Mice lacking p11 showed a weaker inflammatory response when PAR2 signaling was activated
- The study was published in Science Advances (2026), DOI 10.1126/sciadv.aeg6567
- Lead author Marcus Saarinen works at Karolinska Institutet's Department of Clinical Neuroscience
Researchers at Sweden's Karolinska Institutet have identified roughly two dozen previously unknown cell receptors that interact with a small protein called p11. The receptors belong to the G protein-coupled receptor (GPCR) family — the molecular targets of about one-third of all approved medicines, including drugs for pain, inflammation, and depression.
The findings, published in Science Advances, reposition p11 from a narrow mood-related protein, as earlier studies suggested, to a broad amplifier of cellular communication.
Lead author Marcus Saarinen, who works at Karolinska's Department of Clinical Neuroscience, frames the study this way: "Cells communicate through complicated molecular networks, with most modern drugs acting by tuning these signals on or off. Our study identifies a key protein modulating signal transduction across G protein-coupled receptors, the largest receptor family in mammals."
What did the experiments test?
The team screened all 211 human GPCRs in a systematic search for p11 interactions, then validated hits with multiple approaches:
- cell-based assays
- engineered cells lacking p11
- RNA sequencing
- mouse experiments
Out of that screen, they flagged about two dozen GPCRs that bound to p11 in ways no previous study had documented.
Crucially, the protein appeared to bind most strongly when receptors were already activated — a behavior consistent with an amplifying role. When a receptor is "on," p11 seems to push the signal harder; when a receptor is "off," p11 stays largely disengaged.
Which receptor did the team dissect?
The researchers zoomed in on PAR2, a receptor tied to inflammation and pain. In cell tests, adding p11 boosted PAR2-driven responses. In mice engineered to lack p11, triggering PAR2 produced a noticeably weaker inflammatory response than in normal animals.
That two-sided result — stronger signaling with p11 present, weaker signaling without it — strengthens the case that p11 acts as a genuine modulator rather than a passive bystander, the authors argue. It also offers the most concrete mechanism the team uncovered for how p11 might influence inflammatory disease.
Why do these receptors matter for medicine?
GPCRs sit on the surface of most human cells and convert outside signals — hormones, neurotransmitters, inflammatory molecules — into internal cellular responses. Because they shape mood, perception, immune reactions, and more, they have become one of the most heavily targeted protein classes in modern pharmacology.
"Decoding these signaling networks is essential to advance receptor biology and drive the development of next-generation therapies," Saarinen says.
What are the limitations?
The new data come largely from cell cultures and mouse models, which do not always reproduce human biology. It also remains unclear whether boosting or blocking p11 in people would yield safe, predictable effects. The team studied PAR2 in depth but left the other roughly two dozen interacting receptors as open questions for future work.
The next steps, according to Saarinen's group, are animal studies designed to test whether manipulating p11 can ease specific disease symptoms without disturbing other signaling pathways. If those experiments succeed, p11 modulators could eventually join the toolkit for chronic pain, inflammatory disorders, and depression — conditions long linked to GPCR function.
Where can readers find the study?
The paper appears in Science Advances under the title "Systematic identification of p11 as a signaling modulator across the GPCRome." The DOI is 10.1126/sciadv.aeg6567. Funding and institutional support came from Karolinska Institutet.
via Phys.org Biology (Source)
More from James Calloway
Show full bio
Staff writer covering marketplaces and e-commerce at SciBeat.
205 articles
Nearby plates
- Researchers identify brain 'brake' that quiets chronic pain in mice
- GLP-1 Diabetes Drugs Appear Safe in Pregnancy, Review Finds
- Women dominate GLP-1 drug use, yet evidence gaps persist
- MSK Reports Early Promise for KRAS-Targeted Pancreatic Cancer Therapy
- Single Molecule Reverses Prostate Cancer Drug Resistance in Lab